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OBJECTIVE
To identify genetic determinants of increased cardiovascular mortality among
subjects with type 2 diabetes who underwent intensive glycemic therapy in the
Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial.
RESEARCH DESIGN AND METHODS
A total of 6.8 million common variants were analyzed for genome-wide associa-
tionwith cardiovascularmortality among 2,667 self-reportedwhite subjects in the
ACCORD intensive treatment arm. Signiﬁcant loci were examined in the entire
ACCORD white genetic dataset (n = 5,360) for their modulation of cardiovascular
responses to glycemic treatment assignment and in a Joslin Clinic cohort (n = 422)
for their interaction with long-term glycemic control on cardiovascular mortality.
RESULTS
Two loci, at 10q26 and 5q13, attained genome-wide signiﬁcance as determinants
of cardiovascular mortality in the ACCORD intensive arm (P = 9.83 1029 and P =
2 3 1028, respectively). A genetic risk score (GRS) deﬁned by the two variants
was a signiﬁcant modulator of cardiovascular mortality response to treatment
assignment in the entire ACCORD white genetic dataset. Participants with GRS =
0 experienced a fourfold reduction in cardiovascular mortality in response to
intensive treatment (hazard ratio [HR] 0.24 [95% CI 0.07–0.86]), those with
GRS = 1 experienced no difference (HR 0.92 [95% CI 0.54–1.56]), and those with
GRS ‡2 experienced a threefold increase (HR 3.08 [95% CI 1.82–5.21]). The mod-
ulatory effect of the GRS on the association between glycemic control and car-
diovascular mortality was conﬁrmed in the Joslin cohort (P = 0.029).
CONCLUSIONS
Two genetic variants predict the cardiovascular effects of intensive glycemic con-
trol in ACCORD. Further studies are warranted to determine whether these ﬁnd-
ings can be translated into new strategies to prevent cardiovascular complications
of diabetes.
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As diabetes becomes a worldwide epi-
demic, there is a critical need to en-
hance prevention of its cardiovascular
complications as these are responsible
for a large part of the increasedmorbidity,
mortality, and socioeconomic burden of
this disease (1–3). Since hyperglycemia is
the deﬁning characteristic of diabetes,
near normalization of blood glucose lev-
els by intensive glycemic control has
been proposed as one of the interven-
tions that can be used for this purpose. A
meta-analysis of four large randomized
clinical trials in subjects with type 2 di-
abetes has indeed shown that this inter-
vention can lower the risk of myocardial
infarction by 15% and that of major car-
diovascular events by 9% (4). However,
in one of these studies, the Action to
Control Cardiovascular Risk in Diabetes
(ACCORD) trial, intensive glycemic con-
trol was associated with a paradoxical
increase in mortality, mainly due to in-
creased cardiovascular deaths (5). This
prompted early termination of the trial’s
intensive arm 3.7 years postrandomiza-
tion. Results of an intention-to-treat
analysis at 5 years from randomization
showed an 18% signiﬁcant risk reduc-
tion in nonfatal myocardial infarctions,
which, however, was offset by a 29%
significant increase in cardiovascular
mortality (6). While the reasons for this
paradoxical rise in mortality are being
debated (7–11), we sought to identify
genetic predictors of this adverse effect
of intensive glycemic control that could
be used to select individuals with type 2
diabetes who could be safely treated
with this intervention. To this end, we
conducted a genome-wide association
study (GWAS) of cardiovascular mortal-
ity in the ACCORD intensive arm and
analyzed the modulating inﬂuence of
signiﬁcant loci on the effects of inten-
sive and standard treatments on fatal
and nonfatal cardiovascular outcomes.
These loci were further investigated
in a cohort of patients with type 2 di-
abetes from the Joslin Clinic as well as
in the Outcome Reduction With Initial
Glargine Intervention (ORIGIN) trial
cohort.
RESEARCH DESIGN AND METHODS
Study Cohorts
ACCORD Study
ACCORD was designed to test the ef-
fect of intensive glycemic control (tar-
geting glycated hemoglobin [HbA1c]
levels to ,6.0% [42 mmol/mol]) on
cardiovascular outcomes in type 2 di-
abetes, as compared with a standard
therapy aimed at HbA1c levels of 7–7.9%
(53–63 mmol/mol) (5). The study in-
cluded 10,251 participants with type 2
diabetes and high cardiovascular risk
from the U.S. and Canada. Subjects
were randomized in a 1:1 ratio to inten-
sive and standard glycemic arms as well
as to blood pressure and lipid subtrials
in a double 2 3 2 factorial design (5).
Detailed rationale, methods, and results
of the trial have been published previ-
ously (12). DNA samples from 8,174
ACCORD participants (79.7% of 10,251),
who had consented for genetic studies,
were assayed by genome-wide genotyp-
ing. After application of the genotyping
quality control (QC) procedures described
in the SupplementaryData (Supplementary
Material 1, Supplementary Figs. 1–5, and
Supplementary Tables 1–3), 8,084 sam-
ples remained. Baseline characteristics
and distribution between treatment
arms of these 8,084 subjects were similar
to those of subjects who were not in-
cluded in the genetic study, with few ex-
ceptions (Supplementary Table 4). The
effects of intensive glycemic control on
the risk of cardiovascular death and non-
fatal myocardial infarctionwere similar to
those reported in the entire ACCORD
study (hazard ratio [HR] 1.47 [95% CI
1.12–1.93] and HR 0.81 [95% CI 0.68–
0.97], respectively).
Joslin Kidney Study in Type 2 Diabetes
Signiﬁcant single nucleotide polymor-
phisms (SNPs) identiﬁed from theACCORD
GWAS were examined in a cohort of sub-
jects with type 2 diabetes from the Joslin
Kidney Study in Type 2 Diabetes (JKS). This
cohort was a random sample (n = 516) of
Joslin Clinic patients enriched for micro-
andmacroalbuminuria thatwere recruited
between 1993 and 1996 (13). Our study
was limited to 422 study participants
who were self-reported whites and for
whom DNA samples were still available
in 2015.
ORIGIN Study
Signiﬁcant SNPs were further investigated
in the ORIGIN trial (NCT00069784), design
and results of which have been previously
published (14). In brief, 12,537 individu-
als with dysglycemia and additional car-
diovascular risk factors were followed
for a median of 6.2 years for development
of cardiovascular outcomes. Participants
were allocated to insulin-mediated nor-
moglycemia using glargine insulin versus
standard care and n-3 fatty acids versus
placebo using a 2 3 2 factorial design.
The current study was conducted in
1,931 white participants for whom DNA
samples were available. These individu-
als suffered 167 cardiovascular deaths
during up to 7 years of follow-up. Repli-
cation was not sought in any study other
than JKS or ORIGIN.
DNA Extraction and Genotyping
ACCORD Study
Genomic DNA was extracted from white
cells at the University of Washington
using the FlexiGene DNA Kit (Qiagen,
Valencia, CA) (15). Genome-wide geno-
typing was performed in two indepen-
dent laboratories on different platforms:
6,085 samples, corresponding to those
ACCORD participants who had consented
to genetic studies conducted by any in-
vestigator, were genotyped at the Uni-
versity of Virginia (UVA) on Illumina
HumanOmniExpressExome-8 v1.0 chips;
and 8,174 samples, including the above
6,085 samples plus 2,089 samples
from ACCORD participants who had con-
sented to genetic studies only if con-
ducted by ACCORD investigators, were
genotyped at the University of North
Carolina (UNC) on Affymetrix Axiom Bio-
bank1 chips. After extensive within-
laboratory QC, the data were merged
with further between-laboratory QC, re-
sulting in two nonoverlapping sets of sam-
ples: ANYSET, including 5,971 samples
genotyped at either UVA or UNC at a
total of 1,263,585 individual SNPs, and
ACCSET, including 2,113 samples geno-
typed only at UNC at 572,192 SNPs.
The two sets were imputed to over
24 million high quality SNPs using Im-
pute v2.3.1 (16). Additional details about
the genotyping, QC, and merge proce-
dures are provided in the Supplemen-
tary Data (Supplementary Material 1,
Supplementary Figs. 1–5, and Supplemen-
tary Tables 1–3).
JKS
Signiﬁcant variants from the ACCORD
GWAS were genotyped by the Joslin Ad-
vanced Genomics and Genetics Core by
means of custom TaqMan assays (Life
Technologies, Foster City, CA). Genotyping
quality was tested by including six blinded
duplicate samples in each 384-well assay.
The average agreement rate of duplicate
samples was.99%.
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ORIGIN Study
Genotyping was done us ing the
HumanCoreExome Beadchip-12 v1.0 and
v1.1 (Illumina) that measured 551,839
markers, which also allowed the imputa-
tion of ;30 million SNPs using Impute
v2.3.1. The rs57922 SNP was in the im-
puted data and the rs9299870 was not
available, but a proxy in complete link-
age disequilibrium (rs1762431; r2 = 1)
was used in place of this SNP.
Outcomes
ACCORD Study
Cardiovascular mortality, as previously
deﬁned by the ACCORD study group
(12), encompassed all deaths due to
myocardial infarction, congestive heart
failure, arrhythmia, stroke, invasive car-
diovascular interventions, unexpected
deaths due to ischemia occurring within
24 h after symptom onset, and other
vascular causes of death. Nonfatal myo-
cardial infarction was diagnosed by the
presence of cardiac enzyme elevation
and new signiﬁcant Q waves on electro-
cardiography (12).
JKS
Deaths as of December 2011 were de-
termined by matching with the National
Death Index (13). A deathwas attributed
to cardiovascular causes if the primary
cause of deathwas coded as ICD-9 codes
401–448.9 or ICD-10 codes I10–I74.9, or
if cardiovascular disease was listed as
the secondary cause of death and diabe-
tes or renal failure listed as the primary
cause (13).
ORIGIN
A cardiovascular cause of deathwas pre-
sumed if no deﬁnite noncardiovascular
causes were identiﬁed (14). This in-
cluded sudden unexpected deaths, un-
witnessed deaths, and deaths due to
arrhythmia, myocardial infarctions, heart
failure, invasive cardiovascular interven-
tions, stroke, other vascular events, and
unknown causes (14).
Data Analysis
ACCORD Study
The primary goal of the study was to
identify associations between common
genetic variants (minor allele frequency
[MAF] $0.05) and cardiovascular mor-
tality in the intensive treatment arm. To
avoid possible confounding and/or het-
erogeneity in linkage disequilibrium
patterns due to racial differences, the
analysis was restricted to self-reported
non-Hispanic white subjects in this arm
(n = 2,667).
Due to the differences in genotyping
platforms, independent genome-wide
analyses were performed in the two
genotyping sets (including 2,145 and
522 individuals in the ANYSET and
ACCSET, respectively) and results meta-
analyzed. For each variant, the expected
minor allele dosage, ranging from 0 to
2, was computed from the imputed
posterior genotype probabilities. Subse-
quent statistical analyses were con-
ducted using SAS v9.4 (SAS Institute,
Cary, NC). The association between mi-
nor allele dosage and cardiovascular
mortality was evaluated for each variant
by means of Cox proportional hazards
regression assuming an additive genetic
model. As in the original ACCORD analy-
sis (5,6), the regression models included
indicators for the seven clinical cen-
ter networks, blood pressure or lipid
subtrials assignment, and treatment
assignments within these subtrials as
covariates, along with adjustments for
the ﬁrst three principal components,
PC1–PC3, which explain a large part of
the population admixture of the ACCORD
cohort (Supplementary Fig. 4). All cardio-
vascular deaths observed in the intensive
arm until the end of the study in self-
reported non-Hispanic whites (n = 84)
were included in the analysis. After ﬁl-
tering the results by MAF $0.05 and
applying a genomic control correction
(l = 1.02 and 0.92 for ANYSET and
ACCSET, respectively), results from the
two genotyping sets were summarized
by means of a ﬁxed-effects meta-analysis
using an inverse-variance approach in
METAL (17). Meta-analysis results were
considered signiﬁcant if the P value for
the variant was less than the genome-
wide signiﬁcance threshold of 5 3 1028
and notable (suggestive) if ,1 3 1026.
Further analyses of variants showing
signiﬁcant or notable associations were
conducted among self-reported whites
to estimate their effects in the standard
therapy group, test for their interaction
with treatment assignment, and inves-
tigate the effect of a genetic risk score
(GRS) calculated by adding the minor
allele dosage at the two genome-wide
signiﬁcant loci. The effect of signiﬁcant
variants on nonfatal myocardial infarc-
tion was explored in a similar fashion.
Kaplan-Meier plots were generated to
illustrate the effect of signiﬁcant variants
and to estimate the number of cardio-
vascular events caused or prevented by
treating 1,000 subjects with intensive
as opposed to standard therapy for
5 years (18).
The top two variants were further
examined in the Genotype Tissue Ex-
pression (GTEx) database (http://www
.gtexportal.org/home/) (19) for their
correlation with tissue-speciﬁc gene ex-
pression levels. Genes within 1Mb from
either SNP were selected and only tis-
sues that had at least 70 donor samples
in the database with matched gene ex-
pression and genotype data were in-
cluded in the analysis. For each tissue
and gene, the effect of the SNP minor
allele on gene expression was analyzed
by linear regression. Beta estimates
were thenmeta-analyzed across all tissues
by generic inverse-variance methods.
JKS
The average degree of glycemic control
while attending the Joslin Clinic was es-
timated at baseline and at the end of
each year of follow-up as the time-
weighted average of all HbA1c measure-
ments available at the Joslin from
1990 (inception of electronic Joslin lab-
oratory records) up to that point in time.
These yearly HbA1c averages were used
to build a cumulative, time-dependent
index of glycemic control. For measure-
ments taken before 1994, HbA1c values
were derived from HbA1c values as pre-
viously described (20). The interaction
between good glycemic control (deﬁned
as a time-dependent mean HbA1c in the
lowest quartile [,7.5% (58mmol/mol)])
and GRS (constructed from the two lead
SNPs of the ACCORD GWAS) on cardio-
vascular mortality was evaluated by
means of Cox proportional hazards re-
gression adjusting for age and sex. The
JKS ﬁrst quartile (7.5%) corresponds to
the 87th and 43rd percentiles of mean
follow-up HbA1c in the ACCORD inten-
sive and standard arms, respectively.
Thus, this cutoff was a good index within
the JKS to reproduce the contrast between
intensive and standard control while pro-
viding adequate power. The time variable
was deﬁned as the time between study
entry and the date of death, or, for sub-
jectswhodidnot die, thedate of censoring
(31 December 2011).
ORIGIN Study
TheassociationbetweenGRS (constructed
from the two lead SNPs of ACCORD) and
care.diabetesjournals.org Shah and Associates 1917
cardiovascular mortality was analyzed in
ORIGIN by means of Cox proportional
hazards regression adjusting for age, sex,
and treatment assignment. Additional
analyses were performed to determine
whether there was an interaction be-
tween GRS and glargine allocation or
achieved HbA1c (considered as a time-
varying covariate) on cardiovascular
mortality.
RESULTS
Genome-Wide Association Analysis
After ﬁltering by MAF $0.05, a total of
6,839,462 high-quality common variants
were analyzed for association with car-
diovascular mortality among 2,667
self-reported white subjects from the
ACCORD intensive therapy arm. Base-
line characteristics of these subjects
did not differ from individuals in the
standard glycemic arm (Supplementary
Table 5).Manhattanandquantile-quantile
plots summarize the results (Fig. 1). Two
loci reached genome-wide signiﬁcance
(P, 53 1028). One was placed on chro-
mosome 10, within intron 1 of the
MGMT (O-6-methylguanine-DNA meth-
yltransferase) gene (Supplementary
Fig. 6). The lead SNP at this location
(rs9299870) had a MAF of 0.08 and was
associated with a 3.6-fold increased risk
of cardiovascular death per minor allele
copy (P = 9.8 3 1029) (Table 1). The
other locus was placed on chromosome
5, upstream and proximal to three
long intergenic noncoding (LINC) RNAs
(LINC1335, LINC1333, and LINC1331)
(Supplementary Fig. 7). The lead SNP at
this location (rs57922) had aMAF of 0.48
and was associated with a 2.7-fold in-
creased risk of cardiovascular death per
minor allele copy (P = 2 3 1028) (Table
1). The two lead SNPswerewell-imputed
variants in both ANYSET and ACCSET
(Supplementary Table 6). There were
also close-by genotyped markers in
strong linkage disequilibrium that sup-
ported these associations (rs569120 at
5q13 [P = 3.8 3 1028] and rs76496923
at 10q26 [P = 2.6 3 1027]). Both lead
associations were unaffected by ad-
justment for history of cardiovascular
disease at basel ine, age, and sex
(Supplementary Table 7). Neither locus
was associated with noncardiovascular
mortality (HR 1.00 [95% CI 20.59 to
1.69] and HR 0.86 [95% CI 0.65–1.13],
respectively).
Three other loci, placed on chromo-
somes 1, 11, and 5, showed notable yet
non–genome-wide signiﬁcant associa-
tions with cardiovascular mortality
(P values in the 1 3 1026 to 5 3 1028
range). The locus on chromosome 1
reached genome-wide signiﬁcance af-
ter adjustment for baseline history of
cardiovascular disease (P = 3.63 1028)
and further adjustment for age at base-
line and sex (P = 2.4.3 1028). Nineteen
other loci were associated with P val-
ues in the 1 3 1025 to 1 3 1026 range
(Table 1).
Interaction Between Genetic Variants
and Intensive Glycemic Treatment
The two loci with genome-wide signiﬁ-
cance in the intensive arm of ACCORD
were not associated with cardiovascular
mortality in the standard treatment arm
(HR 0.96 and P = 0.91 for rs9299870, and
HR 1.07 and P = 0.72 for rs57922) (Table
1). This translated into gene 3 treat-
ment interaction P values of 0.004 and
0.0004, respectively; although these
P values were likely biased downward
by selecting SNPswithextremeassociation
P values in the intensive glycemic con-
trol arm for interaction analysis. These
interactions are illustrated in Fig. 2 as
the inﬂuence of the two loci on the ef-
fect of intensive therapy on cardiovas-
cular mortality compared with standard
treatment. Allocation to intensive treat-
ment led to a threefold increase in cardio-
vascular mortality among rs9299870 minor
allele carriers (HR 2.96 [95% CI 1.38–6.36]),
whereas it had no detrimental effect on
this outcome among major allele homo-
zygotes (HR 1.14 [95% CI 0.78–1.67])
(Fig. 2A). Similarly, intensive treatment
led to a 2.8-fold increase in cardiovascu-
lar mortality among rs57922minor allele
homozygotes (HR 2.83 [95% 1.56–5.15])
but had no signiﬁcant effect amongmajor
Figure 1—Genome-wide association results. A: The genomic distribution of P values (Manhattan plot) for association with time to cardiovascular
mortality at 6.8 million common polymorphic loci in 2,667 self-reported whites from the ACCORD intensive glycemic treatment arm. P values are
plotted as –log10 values to facilitate visualization. Each dot represents a polymorphism. The top dashed reference line corresponds to the genome-
wide signiﬁcance threshold (P = 5 3 1028), whereas the lower dashed line corresponds to the notable signiﬁcance level (P = 1 3 1026). B: The
relationship between observed and expected P values (quantile-quantile, or Q-Q plot) in the genome-wide analysis. The dotted line corresponds to
the null hypothesis; lambda is the genomic inﬂation factor.
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allele homozygotes or heterozygotes
(HR 0.38 [95% CI 0.14–1.05] and HR
1.26 [95% CI 0.79–2.00], respectively)
(Fig. 2B). Differences among rs9299870
and rs57922 genotypes also appeared to
be present with regard to nonfatal myo-
cardial infarction, with the beneﬁt of in-
tensive glycemic control on this outcome
showing a tendency to be more evident
among carriers of those genotypes that
were protected from the detrimental ef-
fect on cardiovascular mortality (Fig. 2C
and D). However, the evidence for a
SNP 3 treatment interaction on this
outcome did not achieve signiﬁcance
at either locus (P = 0.23 and P = 0.24,
respectively).
An additional genome-wide screen
for variants interacting with treatment
assignment without being signiﬁcantly
associatedwith cardiovascular mortality
in the intensive treatment arm did not
yield genome-wide signiﬁcant results
(Supplementary Fig. 8).
Association Between Genetic Variants
and Gene Expression
In the GTEx database (19), carriers of the
minor allele of the lead SNP rs9299870
showed higher expression of theMGMT
gene (P , 0.01) in tissues such as pan-
creas, spleen, aorta, and subcutaneous
adipose tissue. A meta-analysis of all the
44 tissues available in GTEx yielded a
P value of 43 10217 (I2 = 0%) for associ-
ation between rs9299870 and MGMT
expression (Supplementary Fig. 10).
In a similar meta-analysis of all tissues
in the GTEx database, the top variant
at 5q13 (rs57922) was associated with
expression of the Nop-7–associated
2 (NSA2) gene located 500 kb upstream
of this SNP (P = 2 3 10211; I2 = 17%)
(Supplementary Fig. 11).
GRS for Excess Cardiovascular
Mortality in the Intensive Arm
A quantitative GRS, capturing the joint
effect of rs57922 and rs9299870, was
calculated by adding the minor allele
dosage of the two SNPs. Individuals
were subdivided into three GRS classes
(0, 1, and$2) based on the distribution
shown in Supplementary Fig. 9. Baseline
characteristics of trial participants did
not differ between the three GRS strata
(Supplementary Table 8). Among ACCORD
participants with GRS = 0 (22.6% of
study participants), assignment to in-
tensive therapy was associated with a
fourfold reduction in cardiovascular
mortality (HR 0.24 [95% CI 0.07–0.86])
and twofold reduction in nonfatal myo-
cardial infarction (HR 0.56 [95% CI 0.35–
0.90]) (Fig. 3A). Among participants with
GRS = 1 (47.7% of participants), assign-
ment to intensive glycemic control did
not have any signiﬁcant effect on cardiac
mortality (HR 0.92 [95% CI 0.54–1.56])
while causing a 30% reduction in the
risk of nonfatal myocardial infarctions
(HR 0.70 [95%CI 0.52–0.94]). Among sub-
jectswithGRS$2 (29.6% of participants),
Table 1—Top GWAS loci (P < 13 1025) associated with cardiovascular mortality: effects in the intensive and standard glycemic
treatment arms
Intensive arm (n = 2,667) Standard arm (n = 2,693) Overall
Closest gene* SNP† Position‡ MAF§ HR (95% CI) P HR (95% CI) P P for interaction¶
MGMT rs9299870 10:131269309 0.08 3.58 (2.32–5.55) 9.77E-09 0.96 (0.48–1.92) 0.91 0.0042
LINC01333 rs57922 5:73577939 0.48 2.65 (1.88–3.72) 2.04E-08 1.07 (0.75–1.53) 0.72 0.0004
MASP2 rs373946618 1:11088774 0.08 4.00 (2.40–6.68) 1.15E-07 0.86 (0.33–2.24) 0.75 0.0026
AX748080 rs79525442 11:43990932 0.06 2.98 (1.96–4.54) 3.63E-07 1.62 (0.84–3.13) 0.15 0.0897
CCNJL rs6878970 5:159771753 0.06 3.10 (2.00–4.81) 4.68E-07 1.31 (0.66–2.59) 0.44 0.0399
ANKFN1 rs116899003 17:54448567 0.05 2.86 (1.87–4.39) 1.35E-06 1.34 (0.68–2.64) 0.41 0.0777
GALNT18 rs1487122 11:11472617 0.06 2.98 (1.90–4.69) 2.19E-06 2.10 (1.15–3.85) 0.02 0.3206
LINC01102 rs200457531 2:104694510 0.21 2.27 (1.61–3.20) 2.63E-06 1.03 (0.64–1.66) 0.90 0.0064
KIF2B rs79761505 17:51588871 0.06 2.67 (1.77–4.03) 3.09E-06 1.56 (0.82–2.97) 0.17 0.1779
PCGEM1 rs200184681 2:194259469 0.05 3.29 (1.99–5.43) 3.31E-06 1.09 (0.38–3.13) 0.87 0.0575
RASAL2 rs2209169 1:178601492 0.42 2.09 (1.53–2.86) 4.07E-06 1.36 (0.95–1.96) 0.09 0.0949
TMEM189 rs55757919 20:48748548 0.21 2.13 (1.54–2.95) 4.79E-06 0.91 (0.58–1.42) 0.67 0.0017
ACTL7B rs142631117 9:111614117 0.07 2.63 (1.73–3.98) 5.13E-06 1.09 (0.53–2.26) 0.81 0.0508
IKZF2 rs56175857 2:213929465 0.10 2.58 (1.72–3.88) 5.25E-06 1.02 (0.53–1.96) 0.95 0.0171
MIR548I1 rs140432795 3:125518739 0.05 3.29 (1.97–5.48) 5.25E-06 0.75 (0.27–2.05) 0.57 0.0117
MIR_584 rs72947763 6:115041783 0.06 2.99 (1.86–4.82) 6.17E-06 1.20 (0.54–2.64) 0.65 0.0456
SETBP1 rs56161428 18:42524278 0.06 2.76 (1.78–4.29) 6.31E-06 0.83 (0.37–1.89) 0.66 0.0163
LOC155060 rs6974847 7:148998960 0.25 2.09 (1.52–2.88) 6.92E-06 1.10 (0.73–1.66) 0.64 0.0124
SLC25A26 rs78974441 3:66343805 0.09 2.63 (1.72–4.02) 7.94E-06 1.32 (0.78–2.22) 0.30 0.0432
CNPY1 rs55907517 7:155302020 0.07 2.77 (1.77–4.33) 8.32E-06 0.25 (0.06–1.01) 0.05 0.0040
PER4 rs111891616 7:9437462 0.08 2.67 (1.73–4.11) 8.51E-06 1.45 (0.75–2.81) 0.27 0.1971
ERMAP rs12406643 1:43311563 0.18 2.14 (1.53–2.99) 9.12E-06 0.93 (0.57–1.50) 0.76 0.0103
SUMO1P1 rs62206653 20:52538079 0.06 3.10 (1.88–5.12) 9.33E-06 1.41 (0.68–2.94) 0.36 0.1021
PFKP rs58751041 10:3007494 0.16 2.19 (1.55–3.10) 9.77E-06 0.77 (0.43–1.38) 0.38 0.0018
Primary analysis includes adjustment for assignment to blood pressure and lipid subtrials, interventions within these subtrials, seven clinical center
networks, and top three principal components. These are results ofmeta-analysis of the ANYSET and ACCSET; results within individual sets are shown
in Supplementary Table 5. Other adjusted analyses are shown in Supplementary Table 6. *Closest gene within 500 kbp of the SNP. †One
representative per locus. ‡Position is chromosome:bp. Position according to the National Center for Biotechnology Information assembly build
GRCh37/hg19. §Here MAF is the average of the minor allele frequencies of ANYSET and ACCSET. ¶Effect of SNP 3 treatment interaction.
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assignment to intensive therapy was as-
sociated with a threefold increase in
cardiac mortality (HR 3.08 [95% CI
1.82–5.21]) while yielding no signiﬁcant
beneﬁt on nonfatal myocardial infarction
(HR 0.95 [95% CI 0.66–1.36]). The P values
for GRS by treatment interaction were
3.0 3 1026 for cardiovascular mortality
and 0.07 for nonfatal myocardial infarction,
although the P value for the interaction
effect on cardiovascular mortality was
likely biased downward by creating
the GRS using two SNPs with extreme
P values of association with cardiovascu-
lar mortality in the intensive glycemic
control arm. Adjustment for previously
described risk factors for excess mortality
in the intensive glycemic control arm
(HbA1c .8.5% [69 mmol/mol], presence
of neuropathy, and aspirin use at base-
line) (7) did not attenuate the effect of
the GRS. No signiﬁcant interaction was
observed within each treatment arm
between HbA1c levels during treatment
and GRS.
To assess the potential usefulness of
the GRS to select candidates for inten-
sive glycemic control, we used these
preliminary, yet to be validated ﬁndings
to estimate the possible impact of this
tool on the number of cardiovascular
deaths and nonfatal myocardial infarc-
tions that one could predict, based on
the results above, to be prevented or
caused by treating 1,000 ACCORD par-
ticipants with intensive rather than
standard regimen for 5 years. If applied
to 1,000 subjects with GRS $2, inten-
sive treatment would cause 38 cardiac
deaths, while preventing only 8 nonfatal
myocardial infarctions. By contrast, if
applied to 1,000 ACCORD participants
selected for having GRS = 1 or 0, this
treatmentwould prevent 3 and 14 cardiac
deaths, respectively, along with 21 and
30 nonfatal myocardial infarctions.
Interaction Between GRS and Long-
term Glycemic Control in a Clinical
Care Setting
To evaluate themodulatory effect of the
GRS on the relationship between long-
term glycemic control and cardiovascu-
lar mortality, we examined a cohort of
422 Joslin patients with type 2 diabetes
who experienced 124 cardiovascu-
lar deaths over an average follow-up
of 13 years (Supplementary Table 9).
Long-term glycemic exposure was esti-
mated from the HbA1c measurements
available for this cohort in the Joslin
electronic medical records (median n =
23, IQR 12–37) over a median time pe-
riod of 10 years (IQR 6–16). In this co-
hort, good glycemic control (deﬁned as
an average HbA1c in the lower quartile of
the distribution [,7.5% (58 mmol/mol)]
and considered as a time-dependent
variable)was overall associatedwith a pro-
tective effect on cardiovascular mortality
Figure 2—Inﬂuence of polymorphisms rs9299870 and rs57922 on the effect of intensive glyce-
mic treatment on cardiovascular outcomes. Kaplan-Meier curves for cardiovascular death (A and
B) and nonfatal myocardial infarction (C and D) are shown for intensive (red line) and standard
(blue line) treatment after stratiﬁcation by rs9299870 genotypes or by rs57922 genotypes.
Homozygotes for the rs9299870 minor allele were considered together with heterozygotes
because of their small number. Numbers of subjects at risk at various time points in each
treatment arm are shown in the bottom panel of each plot (1 = intensive and 2 = standard).
HR and 95% CI for the effect of intensive vs. standard glycemic treatment, adjusted for blood
pressure and lipid subtrial assignments and interventions within these trials, clinical center
networks, and the top three principal components. MI, myocardial infarction.
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(HR 0.46 [95% 0.28–0.76], P = 0.002).
However, when stratiﬁed by GRS, good
glycemic control was associated with
lower mortality among subjects with
GRS = 0 or 1 (HR 0.25 [95% CI 0.06–
1.07] and HR 0.29 [95% CI 0.13–0.65],
respectively) but not among patients
with GRS $2 (HR 1.11 [95% CI 0.52–
2.39]) (Fig. 3B). The difference in the
effect of glycemic control among GRS
classes was statistically signiﬁcant (P =
0.029).
Further Evidence for an Effect of the
GRS on Cardiovascular Mortality
The GRS developed in ACCORD was also a
signiﬁcant predictor of cardiovascular
mortality among participants of the
ORIGINtrial,whose levelofglycemiccontrol
during the study was similar to that of par-
ticipants in the ACCORD intensive arm. The
association was in the same direction as in
thatarm,witha1-unit increase inGRSbeing
associated with 27% higher hazards of car-
diovascular death (95% CI 1.03–1.58; P =
0.03), and was independent of assignment
to standard versus glargine arm (P for in-
teraction = 0.57). No signiﬁcant evidence of
interaction between GRS and HbA1c was
observed in this study; although this analy-
sis was limited by the fact that a vast ma-
jorityof participantshadpostrandomization
HbA1c values,7.5% (58 mmol/mol).
CONCLUSIONS
Intensive glycemic control, that is, aim-
ing for an HbA1c ,6.0% (42 mmol/mol)
rather than between 7.0 and 7.9% (53–
63 mmol/mol), signiﬁcantly decreased
the risk of nonfatal cardiovascular events
among high-risk subjects with type 2 dia-
betes in the ACCORD trial (5,6). This ben-
eﬁcial effect, however, was offset by a
paradoxical increase in mortality, mostly
due to cardiovascular deaths. Through a
GWAS approach, we have identiﬁed two
genetic markers that were speciﬁcally as-
sociated with cardiovascular mortality in
the intensive arm of ACCORD and, when
considered together as a score, could
Figure 3—Inﬂuence of the GRS on the effect of glycemic control on cardiovascular outcomes in ACCORD and JKS cohorts. A: Forest plots for
cardiovascular death and nonfatal myocardial infarction in ACCORD, depicting effects of intensive vs. standard glycemic treatment after stratiﬁ-
cation by GRS categories. GRS was obtained by adding the risk allele dosages of the top two genome-wide signiﬁcant variants, rs57922 and
rs9299870, giving a range of 0–4. GRS categories were then assigned as 0, 1, and $2 based on continuous GRS ranges of 0–0.49, 0.5–1.49,
and $1.5, respectively (see Supplementary Fig. 9 for distribution of GRS). B: Effects of good vs. poor glycemic control (as per HbA1c threshold
below and above 7.5% [58mmol/mol]) on cardiovascular mortality in the JKS cohort. Here, GRS categories of 0, 1, and$2 depict the total number of
risk alleles of the two variants combined. HbA1c, time-dependent covariate formulated as yearly time-weighted HbA1c averages estimated from
baseline up until the end of each year of follow-up. MI, myocardial infarction.
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predict whether a participant in this trial
was more likely to derive beneﬁt rather
than harm from the application of inten-
sive glycemic control. Participants with
the lowest score (;20% of the ACCORD
population) derived on average the most
beneﬁt, experiencing a large reduction in
both fatal and nonfatal cardiovascular
events. Those with an intermediate score
(;50% of participants) derived on average
some beneﬁt, experiencing a reduction
in nonfatal events but not in cardiovascu-
larmortality. Thosewith thehighest scores
(;30% of participants) derived on average
harm, experiencing a large increase in car-
diovascular deaths without any reduction
in nonfatal events. The modulatory effect
of these geneticmarkers was independent
of previously identiﬁed predictors of ex-
cess mortality in the ACCORD intensive
arm, such as presence of neuropathy,
aspirin use, and a high HbA1c at baseline
(7,10).
In support of these ﬁndings, we ob-
served a similar inverse relationship
between GRS and long-term cardiovas-
cular beneﬁts of good glycemic control
in the clinical care setting of the Joslin
Clinic. The Joslin cohort, with its rich
HbA1c data, provided a glimpse into
whether the GRS interacts with inten-
sive glycemic control in the “real world,”
adding to the generalizability of our
ﬁndings. Among these patients, a high
GRS was associated with a neutral effect
of good glycemic control rather than a
detrimental one, due perhaps to the
fact that this cohort was not exposed to
a glucose-lowering intervention as in-
tense as in ACCORD. It is remarkable,
however, that despite the differences
in design and setting, similar patterns
of interaction with GRS were observed
in the two studies.
Although there are no other random-
ized controlled trials having the same
exact design as ACCORD, we were able
to corroborate our ﬁndings in another,
albeit different, randomized controlled
trial, the ORIGIN study. ORIGIN investi-
gated whether good glycemic control ob-
tained by means of insulin therapy was
more beneﬁcial on cardiovascular out-
comes than glycemic control obtained
by other means (14). We found that
the GRS was a signiﬁcant predictor of
cardiovascular events also in this study,
regardless of the type of treatment.
Since both arms were on average in
excellent glycemic control at baseline
(median HbA1c 6.4% [46 mmol/mol] in
both arms) as well as during the inter-
vention (median HbA1c 6.0–6.5% [42–
48 mmol/mol]) (14), these results are
consistent with ﬁndings in ACCORD
and the JKS, where associations be-
tween GRS and cardiovascular mortal-
ity were only found in the presence of
good glycemic control and/or intensive
treatment.
These ﬁndings have potential implica-
tions for the treatment of patients with
type 2 diabetes. After the report of in-
creased mortality in response to inten-
sive glycemic control in ACCORD, this
intervention was dismissed as a viable
strategy to decrease cardiovascular risk
in high-risk patients with type 2 diabe-
tes. The results of our study suggest that
it may be possible to revive this thera-
peutic approach by developing a preci-
sion medicine strategy (21), through
which intensive treatment is prescribed
for those patients who will beneﬁt from
it and who are at lower risk of being
harmed. The fact that testing for two
genetic markers is inexpensive and can
be conducted at any point in timemakes
this possibility especially attractive, al-
though the cost-effectiveness of this
approach will have to be evaluated.
However, before this possibility can be
entertained, these ﬁndings must be
replicated by other studies. Also, one
must consider that ACCORD was specif-
ically directed to subjects with type 2
diabetes at high cardiovascular risk
(12) and the genome-wide study was
limited to those participants who con-
sented to genetic studies (80% of the
total) and self-identiﬁed as whites.
Whether the described genetic effects
also concern subjects with diabetes
with different characteristics remains
to be determined.
In addition to their potential as pre-
dictive tools, the two variants that we
have identiﬁed could provide new in-
sights into the mechanisms through
which intensive glycemic control af-
fects cardiovascular outcomes, although
these can only be speculative at this
time. The variant on chromosome 10
(rs9299870) is placed in intron 1 of the
MGMT gene and associated with tissue
expression of this gene as per our anal-
ysis of GTEx data. In addition to being
involved in DNA repair, MGMT functions
as a negative regulator of ESR1 (estro-
gen receptor 1) (22), which has been
linked, although not unequivocally, to
atherosclerosis and thrombosis (23,24).
A search of the RegulomeDB database
(25) shows robust evidence for a regu-
latory function of rs9299870 based on
its occurrence on a DNAse I hypersensi-
tivity cluster where it affects the bind-
ing of the transcriptional coactivator
CREBBP. As this protein has also been
implicated in the increased atherogen-
esis of diabetes (26), our ﬁndings
may point to an as yet undescribed
CREBBP-MGMT-ESR1 pathway linking
glucose metabolism to cardiovascular
outcomes. The other variant (rs57922) is
placed in an intergenic region and associ-
ated with NSA2 expression. Interest-
ingly, NSA2 is a hyperglycemia-induced
gene associated with diabetic nephrop-
athy and involved in the TGF-b1 path-
way (27,28). Also, close to rs57922 is a
cluster of three LINC RNAs. LINCs are
thought to have important regulatory
functions, affecting gene expression
and cellular processes (29,30), and have
been implicated in the pathogenesis of
cardiovascular disease, including vascular
complications of diabetes (31,32).
Our genome-wide screen also iden-
tiﬁed 22 other loci that did not reach
genome-wide signiﬁcance but had
P values,1025 for association with car-
diovascular mortality in the ACCORD
intensive arm. Of these, the MASP2
protein interacts with another CAD-
related gene (MLB2) (33), whereas the
platelet phospho-fructokinase (PFKP)
gene is linked to BMI and interacts with
obesity gene FTO (34).
Strengths of our study include the
randomized design, rigorous clinical trial
protocol for the ACCORD cohort, and
the availability of rich phenotype data
with frequent follow-up and high rates
of adherence (6,12). Another important
strength is the genome-wide approach,
allowing the systematic search for
genetic effects without preconceived a
priori hypotheses. This was further en-
hanced by the use of an enriched variant
set with wide coverage and excellent
imputation quality, and by the applica-
tion of stringent criteria to evaluate sig-
niﬁcance. Overall, since this analysis
tested the effect of genes on clinical car-
diovascular outcomes in a cohort enrolled
and monitored under rigorous clinical
trial conditions, one could anticipate a
strong possibility of uncovering novel
associations that would be missed or
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diluted in typical heterogeneous cross-
sectional GWAS, even large ones.
Nonetheless, some limitations should
be acknowledged. In addition to the
need for replication and the uncertain
generalizability mentioned above, one
should consider that, due to the rela-
tively small number of events and the
stringent signiﬁcance threshold, the
study was powered to detect only large
genetic effects. We cannot exclude the
existence of other variants exerting a
smaller but still relevant inﬂuence on
the cardiovascular effects of intensive
glycemic control. Similarly, one cannot
exclude additional genetic inﬂuences by
low-frequency variants, which were not
included in the present analysis. Finally,
although our GWAS identiﬁed two loci
with robust statistical associations with
cardiovascular mortality in the intensive
glycemic arm of ACCORD, the tests for
interaction between treatment and
these two loci (singly or combined in a
GRS) likely provided downwardly biased
P values, due to a form of “winner’s
curse.” The test of gene-treatment inter-
action in the Joslin cohort is not biased,
however, and the results from this study
suggest that the observed interaction is
not solely due to statistical artifact.
In summary, we have identiﬁed two
genome-wide signiﬁcant loci associated
with increased risk of cardiovascular
death in the intensive glycemic treat-
ment arm of ACCORD. Our additional
analyses suggest that these loci could
be potentially used as screening tools
to identify subjects with type 2 diabetes
who may highly beneﬁt from intensive
glycemic control rather than derive
harm from it, although further valida-
tion is needed. These two loci also point
to novel candidate pathways linking glyce-
mic control to cardiovascular outcomes,
the study of which may lead to the devel-
opment of new interventions to prevent
cardiovascular disease in diabetes.
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